ArticleObesity surgery2026
Time Free from High-Risk Obesity after One-Step Vs. Two-Step Duodenal Switch: A Propensity-Score Single-Center Analysis.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuodenal switch (DS) can be performed as a direct one-stage procedure or as a planned/revisional two-step approach after sleeve gastrectomy. Consistent head-to-head evidence on long-term disease-free time is limited.
objectivesTo compare disease-free time and safety between direct (one-stage) and two-step DS.
settingSpanish tertiary bariatric center.
methodsPropensity-score matched analysis (1:1) of patients undergoing DS, comparing direct versus two-step procedures. Matching variables were age, sex, and baseline body mass index (BMI). From 429 DS cases, 75 direct DS patients were matched to 75 two-step patients. Outcomes included short- and long-term complications, mortality, severe diarrhea or malnutrition, follow-up completeness at 3 and 5 years, weight loss, BMI < 35 kg/m², and disease-free status operationalized as the absence of metabolic diseases across follow-up.
resultsMean initial BMI was 55.9 kg/m². Safety was comparable: short-term complications 14% (6% Clavien-Dindo ≥ III) and long-term 5.3%, with no between-group differences; no mortality, severe diarrhea, or malnutrition.Follow-up was 94.6% at 3 years and 80.7% at 5 years. Direct DS showed superior disease-free status at 5 years (absence of metabolic diseases 66.7% vs 57.1%; p<0.001) and greater durability of weight control (BMI < 35 kg/m² 88.2% vs 71.4%; p<0.001), along with higher total weight loss (45.4% vs 42.0%; p<0.05).
conclusionsIn patients with BMI > 50 kg/m², direct DS achieves longer high-risk disease-free status while maintaining a safety profile comparable to two-step DS.
Indexed as
Identifiers
41495319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.